Abstract Library

#4446 Uncommon ophthalmic presentation of a small bowel neuroendocrine tumour: Case report

Introduction: Neuroendocrine tumours (NETs), including carcinoid tumours, are slow-growing neoplasms commonly originating in the gastrointestinal tract or bronchus, but they can also arise in other sites. Due to their indolent nature, the majority of NETs are diagnosed at an advanced stage, typically to the lymph nodes, liver, or bones.

Conference:

Presenting Author:

Authors: Hamidatou K, Behourah Z, Ahed Messaoud M, Megaiz A, Lechar M,

Keywords: Neuroendocrine tumour, Carcinoid tumour, Orbital metastasis, somatostatin analogue injection,

#4387 Exenatide-test for diagnosing endogenous hyperinsulinemic hypoglycaemia: A randomised placebo-controlled cross-over proof-of-principle study – FAST study

Introduction: The gold standard to diagnose endogenous hyperinsulinemic hypoglycaemia (EHH) is the fasting test which is cumbersome and incurs high costs. In the setting of radio-labelled 68Ga-exendin-4 PET/CT in patients with EHH (to localise insulinoma), we unexpectedly observed clinically relevant hypoglycaemia following administration of the tracer, which does usually not occur after GLP-1 agonist therapy in type 2 diabetic patients and in healthy subjects.

Conference:

Presenting Author: Christ E

Authors: Hepprich M, Romberg C, Fricke J, Freitag M, Mudry J,

Keywords: endogenous hyperinsulinemic hypoglycaemia, insulinoma, Exendin, Fasting test,

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#4343 Ga68-DOTATATE imaging on a state-of-the-art total-body PET/CT scanner with reducing administered activity

Introduction: Long-field of view PET/CT scanners allows total body scanning resulting higher sensitivity than traditional PET/CT scanners offering possible lower dose and faster scans.

Conference:

Presenting Author: Santillan N

Authors: Navalkissoor S, Santillan N, Chowdhury A, Ferreira B, Toumpanakis C,

Keywords: SSR, Ga68 DOTATATE, Neuroendocrine tumour, Quadra,

#4336 Life-threatening hypoglycaemia due to insulinoma successfully treated with PRRT

Introduction: Malignant insulinoma is an uncommon tumour that is usually accompanied by severe hypoglycaemia.

Conference:

Presenting Author:

Authors: Ledwon A, Michalik B, Kropinska A, Paliczka-Cieslik E, Blewaska A,

Keywords: insulinoma, sever hypoglycaemia, PRRT,